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Vancomycin hydrochloride （VANH）, the first glycopeptide antibiotic, is a water-soluble
drug for the treatment of acute osteomyelitis. Liposomal formulations of VANH have
already been manipulated and characterized, which was a mean of increasing their ther-
apeutic index, reducing their toxicity and altering drug biodistribution. One of the chal-
lenges for preparing VANH-Lips is their low encapsulation efficiency (EE). In the present
study, we aim to improve the liposomal formulation of VANH for higher EE, longer sys-
temic circulation, reduced nephrotoxicity and enhanced antimicrobial activities. Vanco-
mycin hydrochloride-loaded liposomes (VANH-Lips) were formulated by the method of
modified reverse phase evaporation. Based on the optimization of formulation with
orthogonal experimental design, the average drug encapsulation efficiency and the mean
particle size of VANH-Lips were found to be 40.78 ± 2.56% and 188.4 ± 2.77 nm. In vitro drug
release of VANH-Lips possessed a sustained release characteristic and their release
behavior was in accordance with the Weibull equation. After intravenous injection to mice,
the mean residence time (MRT) of VANH-Lips group was significantly prolonged in vivo and
the AUC value was improved as well compared with the vancomycin hydrochloride solu-
tion (VANH-Sol) group. Furthermore, the biodistribution results in mice showed that
VANH-Lips decreased the accumulation of VANH in kidney after intravenous injection. In
conclusion, VANH-Lips may be a potential delivery system for VANH to decrease neph-
rotoxicity in the treatment of osteomyelitis.
© 2015 Shenyang Pharmaceutical University. Production and hosting by Elsevier B.V. This is
an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/3.0/).aceutical Science, Shand
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Osteomyelitis is an infection of the bone and bone marrow,
which is attributed to bacteria contamination result from
trauma, surgery, orthopedic fixation device implantation. In
consequence it brings huge challenges to orthopedic surgeons
[1]. Regular treatment includes thorough debridement,
continuous perfusion, and intravenous application of sensi-
tive antibiotic for 4e6 weeks. Based on complete removal of
the lesion, effective systemic application of antibiotics is the
necessity of the treatment of chronic osteomyelitis. Antibi-
otics are administered to control inflammation and to prevent
exacerbation in chronic infections [2]. However, the efficacy of
antibiotics is severely limited by its poor penetration. Long-
term and high-dose strategy is, thus, required to improve
the therapeutic outcome [3]. Although there are plenty of
antibiotics and the current surgical techniques are promising,
patients having osteomyelitis are still suffered from high
recurrence rate. This is due to drug resistance induced by
frequent administrations of sensitive antibiotics. To be
treated clinically, therefore, osteomyelitis has been normally
considered as one of the most obstinate orthopedic and
postoperative complications [4].
As the first glycopeptide antibiotic, VANHwas developed in
the 1950s [5]. Even if the concentration of vancomycin is low, it
is still valid against themajority of Gram-positive bacteria, for
example, Staphylococcus aureus and other staphylococcus
species [5]. S. aureus is one of the most frequent pathogenic
bacterium of osteomyelitis [6]. Although it works specifically
on bacterial cell wall peptidoglycan, but, the side effects,
including most notably nephrotoxicity, ototoxicity, and
neuromuscular blockade, appeared in the early course of its
application. These side effects limit its wide application [5,7].
Renal elimination of vancomycin is mainly through
glomerular filtration and partly mediated by active tubular
secretion [8]. Most of VANH is removed unchanged in the
urine [9]. Renal dysfunction is a major omen of vancomycin
treatment failure [10]. Gene expression profiling studies in
animals with high-dose VANH suggest that cellular necrosis
resulted from VANH accumulation in proximal tubular cells
may be the underlying mechanism of nephrotoxicity [11].
Many of previous reports has demonstrated a highly signifi-
cant relationship between vancomycin dose and the time to
nephrotoxicity [12,13]. In-patients who suffer from chronic
osteomyelitis often have low immunity. Therefore it easily
leads to chronic kidney disease and acute kidney injury. In
addition, Clinical failure reasons have also been reported
owing to its slow, time-dependent bactericidal activity, poor
intracellular penetration into macrophages [14]. Therefore,
merely increasing the parenteral treatment doses of vanco-
mycin offers an essentially increased risk of drug toxicity that
is not offset by any appreciable benefit [15].
Liposomes have been proven to be a hopeful drug delivery
system for a variety of drugs including antibiotics [16]. As their
lipid bilayer are made up of phospholipid and cholesterol,
which is similar to the cell membrane and can readily fuse
with infectious microbes, Liposomes are considered to be a
non-toxic and biodegradable drug carrier for sustained and
targeted delivery. They are also the most widely usedantimicrobial drug delivery vehicles [17]. Encapsulation of
antibiotics in liposomes is known to enhance their antimi-
crobial activities while minimizing their toxic effects [7]. In
addition, the sustained release of antibiotics from the lipo-
somes may prolong the half-lives of these drugs in the body.
Encapsulation of VANH into liposomes has been attempted
by our group as well as several other investigators as a mean
of increasing their therapeutic index, reducing their toxicity
and altering drug biodistribution [14,15,18e20]. Nevertheless,
due to the highly hydrophilic property, one of the challenges
preparing VANH-Lips is their low encapsulation efficiency. If
so, this will require high amount of liposomal formulations to
achieve satisfactory therapeutic dose, a reason that prone to
drug resistance. In the present work, several methods have
been attempted for this challenging endeavor. The EE of the
liposomes prepared by Andrew Pumerantz [15] and Krishna
Muppidi [14] are both 9%. The EE for vancomycin hydrochlo-
ride into liposomes prepared by thin film dispersionmethod is
2.34% [19]. Yang DM [20] prepared the multivesicular lipo-
somes, whose mean EE and particle size is 24.9% and 3.3 mm,
respectively. The EE of cationic liposomes prepared by Tao Ma
[18] is 7.58%. The objective of this study was to prepare
vancomycin-encapsulated liposomes with relatively high
encapsulation efficiency and performed an in vivo study using
healthy mice to compare their pharmacokinetic and bio-
distribution profiles with those of mice treated with the
standard vancomycin solution. The optimal liposomes pre-
pared by modified reverse phase evaporation methods were
composed of injectable soybean phosphatides, cholesterol
and VANH. The composition of the formulation is non-toxic,
and the preparation process is simple and controllable. The
optimal formulations with appropriate drug encapsulation
percentage and homogenous particle size distribution were
selected to investigate the pharmacokinetics and bio-
distribution after intravenous administration, utilizing mice
as animal models compared with free vancomycin hydro-
chloride, in order to provide the basic knowledge for further
development and evaluation of liposome-encapsulated VANH
formulation.2. Materials and methods
2.1. Materials
Soybean lecithin (Injection grade, phosphatidylcholine ac-
counts for 95% pH 5.0e7.0) was provided by Shanghai Taiwei
Pharmaceutical Co., Ltd, Shanghai, China. Cholesterol was
purchased from Shanghai Medical Chemical Reagent Co., Ltd.
(China). VANHwas purchased fromShanghai ziyi Reagent Co.,
Ltd. (China). The other chemicals were of analytical reagent
grade or higher.
Animal: Kunming strain mice (weighed between 18 and
22 g, female ormalewere provided by theMedical Animal Test
Center of Shandong University) were used for the in vivo
pharmacokinetics and biodistribution studies. The animals
were fasted 12 h before drug administration. The animal
experiment protocol was reviewed and approved by the
Institutional Animal Care and Use Committee of Shandong
University.
Table 1 e Factors and levels of the orthogonal
experimental design.
Levels Factor
A B C D
1 1:2 1:10 1:2 35
2 1:4 1:15 1:3 45
3 1:6 1:20 1:4 55
(A) the ratio of cholesterol to lecithin (w/w), (B) the ratio of drug to
lipids (w/w), (C) the ratio of water phase to oil phase(v/v) and (D)
hydration temperature(C).
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Formulation of VANH-liposomes were prepared using various
methods.
2.2.1. Freeze-thaw method [21]
Pre-formed empty liposomes were prepared by the film-
hydration method. Briefly, lipid (soybean lecithin and choles-
terol) was mixed with chloroform and evaporated using a ro-
tary evaporator (Shanghai Yarong Instrument Co., Shanghai,
China) at an elevated temperature (40 C). During evaporation,
a lowvacuumwasapplied initially to avoid burstingof the lipid
solution. The dried lipid was placed under vacuum overnight
to remove residual solvent. Then VANH-Sol was added to hy-
drate for 10 min and the mixture was frozen at 20 C for
20 min. The liposomes were then sonicated at 5 min followed
by two freeze-thaw cycles (20 C for 20min, 45 C for 10min).
2.2.2. Proliposome method
Defined amounts of phospholipids and cholesterol were
weighed into a round-bottom flask and dissolved in chloro-
form, forming a transparent solution, which was described by
Isailovic et al. [22]. Prescribed amount of sorbitol powder was
added in the solution. The organic solvent was then removed
under reduced pressure by the rotary evaporator to form
proliposome. Afterwards, VANH-Sol was poured into the
proliposome solution, and the mixture was sonicated to form
uniform liposome.
2.2.3. Remote loading method by ammonium sulfate
gradients
This method included two steps [23]. The first step was the
formation of empty liposomes. The liposomes were prepared
by dissolving phospholipids/cholesterol in chloroform. The
organic solvent was then removed in a 40 Cwater bath under
reduced pressure by the rotary evaporator to form lipid
membrane. The lipid membrane was then hydrated in
ammonium sulfate solution. And the mixture was sonicated
to form translucent solution. Taken suitable amounts of
liposomes in dialysis bag, and dialysis in distilled water for
12 h at room temperature, and the empty liposomes were
prepared. The second step was drug loading. Briefly, take
empty liposomes, adding to VANH-Sol, and incubate in water
bath, then the drugs could across the lipid bilayer and were
entrapped into the vesicles.
2.2.4. pH-gradient method
Suitable amounts of phospholipids and cholesterol were
weighed into a round-bottom flask and dissolved in chloro-
form, as described by Zhou [24]. Then chloroform was
removed in a 40 C water bath under reduced pressure by the
rotary evaporator to form lipid membrane. The lipid mem-
brane was then hydrated in the citric acid solution
（300 mmol/L） to produce multivesicular vesicles. The lipo-
somes were then homogenized at 800e1000 bar. In order to
form the transmembrane pH-gradient between the external
phase and internal phase of liposome, Na2HPO4 solution
(0.5 mol/L) was added into the system to adjust the external
pH of liposomes to 6.5. Then, the systemwas incubated under
50 C for 10 min.2.2.5. Reverse phase evaporation method
Appropriate amounts of phospholipids and cholesterol were
weighed into a round-bottom flask and dissolved in chloro-
form [25]. Subsequently, VANH-Sol was directly added to the
dispersed solution of phospholipids, and the mixture was
sonicated 3 min at room temperature in an ultrasonic bath
(Kun Shan Ultrasonic Instruments Co., Ltd). The organic sol-
vent was then removed in a 40 C water bath under reduced
pressure by the rotary evaporator. Sufficient amounts of water
was added to hydrate for an additional 10 min. Then, the
liposomal emulsion was maintained under control tempera-
ture to make the liposome structure more stable.
2.2.6. Modified reverse phase evaporation-rehydration
method
Similar to reverse phase evaporation method, except for the
difference that VANH-Sol was dispersed with a microinjector
(Kd Scientific 781100, Fabrique' Auxetats-Units Co. Ltd., USA)
into the dispersed solution of phospholipids. And the mixture
was sonicated to form a primary emulsion at room tempera-
ture in an ultrasonic bath.2.3. Optimization of formulation with orthogonal
experimental design
On the basis of preliminary test, modified reverse phase
evaporation method reached the highest EE. Four selective
formulation factors that mainly affected EE were chosen as
research objects, including (A) the ratio of cholesterol to leci-
thin (w/w), (B) the ratio of drug to lipids (w/w), (C) the ratio of
water phase to oil phase (v/v) and (D) hydration temperature.
In this place, water phase is VANH-Sol and oil phase is the
chloroform solution of phospholipid and cholesterol. Nine
formulations were designed for test according to L9 (34)
orthogonal experimental design, in order to screen the
optimal formulation. On the basis of size plus EE as the eval-
uation index, the factors and levels of the orthogonal experi-
mental design are listed in Table 1.2.4. Freeze-drying of VANH-Lips
In the freeze-drying process, mannitol (5%, w/v) was used as a
cryoprotectant. First the fresh prepared VANH-Lips with 5%
mannitol were pre-frozen using an ultra-cold freezer (MDF-
382E, Sanyo Electric Co., Ltd., Osaka, Japan) for 24 h at 80 C.
Then, the resultant sampleswere transferred to the lyophilizer
a s i a n j o u rn a l o f p h a rma c e u t i c a l s c i e n c e s 1 0 ( 2 0 1 5 ) 2 1 2e2 2 2 215(FD5-2.5, GOLD SIM, Issaquah, WA) at 50 C for 48 h. The
lyophilized powder was collected for further experiments.
2.5. Characterization of VANH-Lips
2.5.1. Visualization of liposomes by transmission electron
microscopy (TEM)
TEM (H-7000, Hitachi, Japan) was used as a visualizing aid for
vesicles. Samples were negatively stained with a 2% aqueous
solution of phosphotungstic acid. Vesicular suspension sam-
ples were dried on a carbon-coated grid for staining. The
excess solution was removed by blotting. After drying, the
specimen was viewed under the TEM.
2.5.2. Measurement of particle size and pH value
Measurements were performed using a Beckman Delsa™
Nano C Particle Analyzer (Beckman Coulter A53878, Otsuka
Blectronics Co. Ltd., USA). Samples were placed in plastic
disposable cuvettes and equilibrated at 25 C. Particle size
measurements included z-average, PDI, and PDI width. The
pH value of VANH-Lips was determined with a digital pH
meter (FE20, Mettler Toledo, Greifensee, Switzerland). Each
measurement was made at least in triplicate at 25 C.
2.5.3. Determination of encapsulation efficiency (EE)
The EE of VANH-Lips were determined by ultrafiltration-HPLC
method using an Agilent G1310A pump and an Agilent G1314A
variable wavelength detector set at 230 nm. VANH was
monitored at a wavelength of 230 nm with the column,
InertSustain®-C18 column (4.6 mm  250 mm) (Shimazu-GL,
JAPAN). The mobile phase was composed of 0.05 mol/L po-
tassium phosphate monobasic monopotassium phosphate
solution (pH 3.2) and methanol (spectroscopic grade) (78:22,
ml/ml) at a flow rate of 1.0 ml/min. As follows, 0.1 ml of
liposome was mixed with 2 ml methanol, adding distilled
water volume to 10 ml. The total drug contents in liposomes
were measured by HPLC. 0.1 ml of liposome was mixed with
0.5 ml distilled water into ultrafiltration centrifuge tube
(MILLIPORE, UFC901024 15 M 10 K), and was centrifuged at
4000 rpm for 40 min (3K30, Sigma, Germany). Then another
200 ml distilled water was added into the mixture and centri-
fuged at 4000 rpm for 20 min again. The free drug content in
the outer tube was also measured by HPLC. The EE and DL
were calculated by using under-mentioned equations (1) and
(2) respectively.
EEð％Þ＝Wtotal Wfree
Wtotal
 100% (1)
DLð％Þ＝Wtotal Wfree
Wlipid
 100% (2)
wherewtotal was the analyzedweight of drug in liposomes,wfree
was the analyzed weight of free drug, wlipid was the weight of
lipid added in system.
2.5.4. The drug release experiment in vitro from VANH-Lips
The in vitro release study of VANH-Lips was carried out at
37 C using dynamic dialysis technique [26,27]. The liposomes
with encapsulation efficiency 40.31% were used for this
analysis. Briefly, the VANH-Lip dispersion (2 ml, donorsolution) was kept in a dialysis membrane (MD34,
8000e14,000, AMERICA) with a molecular weight cut-off of
8000e14,000 Da and this system was immersed in 30 ml of pH
7.4 buffer solution. The medium was kept at 37 C under
continuous magnetic stirring of 100 rpm. At a regular interval
of time, 0.5 ml of receiver solution was withdrawn and same
volume of fresh medium was replaced. The VANH-Sol ob-
tained from a dialysis test was used as control. The percentage
of drug released was determined using the HPLC conditions
mentioned previously. The mean calculated values were ob-
tained from 3 replicates. The cumulative fraction of release
rate was calculated from the following equation and the re-
sults are expressed as mean ± standard deviation (SD):
Release rate
 
%
!
¼ cnv0 þ
Pn1
i¼0 civi
c0v0
 100%
cn is the drug concentration in the release medium of each
time interval, v0 is the total volume of the release medium, vi
is the volume of the withdrawn medium, ci is the drug con-
centration in the release medium at time.2.6. Pharmacokinetics studies and drug distribution
studies in mice
Kunming strain mice, weighing between 18 and 22 g, were
randomly divided into two groups. Group 1 was treated with
VANH-Sol while group 2 was treated with the VANH-Lips. The
concentration of VANH in liposome is 0.96 mg/ml, while the
VANHwas dissolved in the sterile water for injection to obtain
the same concentration. Each preparation was injected
through the tail vein at the VANH dose of 15 mg/kg mouse.
Blood samples were taken from the terminal retro-orbital
bleeding at various times (0.083, 0.25, 0.5, 1, 2, 3, 4, 6, 8 and
10 h) into micro-tubes containing sodium heparin as an
anticoagulant, and centrifuged immediately (10 min,
12,000 rpm). 0.2 ml 10% zinc sulfate solution was added to an
aliquot (0.2 ml) of each plasma sample andmixed for 3 min by
vortex to extract VANH. Following centrifugation at 12000 rpm
for 10 min, the organic phase was transferred to a glass tube
and the solvent was evaporated under nitrogen stream at
40 C. The dry sample was then dissolved in 100 ml mobile
phase and 20 ml of the solution was injected into the HPLC
column to measure VANH peak area and calculate its con-
centration by standard curve method.
The heart, liver, spleen, lungs, kidneys and brain of each
mouse was rapidly excised following blood collections, and
immediately washed twice with normal saline (0.9% NaCl),
wipedwith filter paper, weighed and homogenizedwith 1.0ml
normal saline (0.9% NaCl), except for liver (2 ml). 0.2 ml 10%
zinc sulfate solution was added to an aliquot (0.2 ml) of each
plasma sample and mixed for 3 min by vortex to extract
vancomycin hydrochloride. After vortexing (IKA®VORTEX1,
GEMANY) for 3 min, the sample was centrifuged for approxi-
mately 10 min at 12,000 rpm. The supernatant was collected
and the solvent was evaporated under nitrogen gas at 40 C.
The dry sample was reconstituted in 100 mL mobile phase for
measurement of VANH by HPLC.
The concentration of VANH was measured by the method
of reversed-phase HPLC with the column, InertSustain®-C18
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wavelength of 230 nm. The mobile phase was composed of
0.05 mol/L potassium phosphate monobasic monopotassium
phosphate solution (pH 3.2) and methanol (spectroscopic
grade) (82:18, ml/ml) at a flow rate of 1.0 ml/min. Aliquots of
deposed supernatants (20 mL) were loaded on the HPLC. The
detection limit of VANH was 0.4 ng. Intraday and interday
variabilities were less than 3% and 5%, respectively. Mean
recovery rates of each organ exceeded 80%, RSD <5%.
2.7. Statistical analysis
Data were expressed as mean ± standard deviation (SD). The
statistical analysis of significance among various treatments
was performed using unpaired Student's t-test with P < 0.05
indicating significant difference. An analysis of variance
(ANOVA) test was also used if necessary. Pharmacokinetic
parameters of VANH-Lip were obtained using DAS2.0 (drug
and statistics for windows) program.Preparation methods
Fig. 1 e Encapsulation efficiency of VANH-Lips prepared by
differentmethods. (A. Freeze-thawmethod. B. Proliposome
method. C. Reverse phase evaporationmethod. D. Modified
reverse phase evaporation-rehydration method. E. Remote
loading method by ammonium sulfate gradients. F. pH-
Gradient Method).3. Results and discussions
3.1. Encapsulation efficiency (EE) of VANH-Lips
VANH is highly hydrophilic and water soluble. According to
the results showed in previous report [14,15,18e20], the EE of
liposome-loaded water-soluble drugs is low. There are many
approaches for the preparation liposomal formulation of
VANH including thin film dispersion method [19], double
emulsion method [20] and reverse phase method [18]. So it is
very difficult to prepare high EE, stable VANH-Lips by classic
passive loading method due to the fact that VANH is
hydrosoluble.
So we attempt different ways to improve the EE, including
freeze-thaw method, proliposome method, modified reverse
phase evaporation-rehydration method, remote loading
methods by ammonium sulfate gradients and pH-gradient
method. Modified reverse phase evaporation method, is used
to prepare liposomes with a large internal aqueous space，
which is advantageous to encapsulate water-soluble drugs
[25]. Based on reverse phase evaporationmethod described by
Szoka and Papahadjopoulos [25], the difference was that
VANH-Sol was uniformly dispersed with a microinjector to
make the liposome with better formability, emulsification
time was increased to reduce the size of VANH-Lips, and the
hydration time was shorten to improve the EE.
Modified reverse phase evaporation method can make the
drug dispersed more uniform. Then a more uniform film was
formed after rotary evaporation and the particle size was
smaller after hydration. Thus we can reduce ultrasonic time
after hydration to avoid leakage of drugs, making drug
encapsulation efficiency improved.
According to the results showed in Fig. 1, the EE of the
liposome prepared by freeze-thawnmethod is the highest, the
second is modified reverse phase evaporation method. In the
preparation of liposomes, freeze-thaw cycling is implemented
to reduce the lamellarity of liposomes, form a less poly-
dispersed systemand/or disrupt the liposomal bilayer to allow
drug molecules to diffuse into the liposome, promotingencapsulation. Three batches of liposomes were prepared by
freeze-thaw method. The particle size of the three batches
were 321.6, 457.7, 489.5 nm, respectively. The mean size was
422.9 nm, and RSD is 21.09%. So the size of the liposome
prepared by freeze-thawmethod is difficult to control, and the
reproducibility is poor. Regarding the efficiency of drug
encapsulated as shown in Fig. 1, correlating to the different
preparation methods, the mean encapsulation percentage of
VANH prepared by modified reverse phase techniques was
elevated significantly and the particle size distribution was
more homogeneous as compared to that of thin film or pro-
liposome method. However, it should be noted the fine drug
encapsulation efficiency of liposome was obtained using
1:15 M ratio of VANH and phospholipids. Therefore, modified
reverse phase evaporation method is the best choice.3.2. Results of the test of orthogonal design of VANH-Lip
Based on the preliminary experimental results, the EE can be
improved through formulation and preparation optimization.
On the basis of studying many documents, four selective
formulation factors that mainly affected EE and size were
chosen as research objects, including (A), (B), (C) and (D).
Furthermore, the formulation factors affecting EE were stud-
ied in orthogonal experimental design. The results are showed
in Table 2.
The results were calculated by range analysis. According
to Table 2, the effect of (A) the ratio of cholesterol to lecithin
(w/w) was extremely significant; the effect of other factors is
Table 2 e Results of the test of orthogonal design of VANH-Lips.
Experiment number A B C D EE (%) Size (nm) Size-EE
1 1 1 1 1 37.09 372.2 335.11
2 1 2 2 2 41.96 237.5 195.54
3 1 3 3 3 35.1 192.9 157.83
4 2 1 2 3 38.14 242.0 203.89
5 2 2 3 1 42.78 182.7 139.89
6 2 3 1 2 42.25 162.0 119.78
7 3 1 3 2 28.17 163.4 135.26
8 3 2 1 3 36.45 152.9 116.45
9 3 3 2 1 36.07 172.4 136.30
K1 229.49 224.76 190.45 203.76
K2 154.52 150.63 178.58 150.20
K3 129.34 137.97 144.33 159.39
R 100.16 86.78 46.12 53.57
(A) the ratio of cholesterol to lecithin (w/w). (B) the ratio of drug to lipids (w/w). (C) the ratio of water phase to oil phase(v/v). (D) hydration
temperature.
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affecting on index and range was bigger, extent affected was
greater. The effects of each factor on the EE were as follows:
(A) the ratio of cholesterol to lecithin (w/w) > (B) the ratio of
drug to lipids (w/w) > (D) hydration temperature > (C) the ratio
of water phase to oil phase (v/v). K1, K2, K3 represented the
sum value of each level. On the basis of the synthetic mean
value of a certain factor (A or B or C or D), the optimized level
combination of each factor was chosen. The lower the syn-
theticmean value, the better the level was and a higher EE can
be achieved in this level. Analytical results of three factors
were A: 1 > 2 > 3; B: 1 > 2 > 3; C: 1 > 2 > 3; D: 1 > 3 > 2, so the
optimal parameters is A3B3C3D2. Furthermore, the encapsu-
lation percentage was elevated accompanied with the incre-
ment of phospholipid amount. So the optimal formulation is
adjusted slightly to improve drug loading efficiency, precisely
the ratio of cholesterol to lecithin is 1:6.5, the ratio of drug to
lipids (w/w) is 1:15, hydration temperature 45 C, the ratio of
water phase to oil phase (v/v) is 1:4. The EE of the liposome
prepared by the optimum formulation reached to 40.78%. The
optimum formulation is feasible and the EE of the liposome
prepared by the optimum formulation is higher. Furthermore,
with the optimization of formulation, the achievement of
liposomes with higher EE by reverse phase evaporation
method would be helpful to improve pharmaceutical andFig. 2 e Photographs of VANH-Lips: (A) fresh-prepared, (B)
lyophilized powder, and (C) the suspension of lyophilized
powder.pharmacological effects in curing Osteomyelitis. In short, the
reverse phase evaporation method was superior to previous
reports in encapsulating vancomycin hydrochloride.
3.3. Characterization of VANH-loaded liposome
3.3.1. Morphology and physicochemical property of VANH-
Lips
The photographs of fresh-prepared VANH-Lips, the VANH-
Lips freeze-dried powder and the suspension of VANH-Lips
freeze-dried powder (dispersed with distilled water) are
shown in Fig. 2. The particle size of the fresh-prepared VANH-
Lips was 188.4 nm, indicating light blue opalescence. The
lyophilized powder of VANH-Lips appeared as full, no collapse
of the porous solid block. The lyophilized powder displayed
good redispersibility and the reconstituted VANH-Lips with
distilled water were still an opalescent colloidal solution. The
morphology of VANH-Lips was observed by TEM and the
observation results were displayed in Fig. 3. The TEM image
shows that most liposomes were spherical particles with
approximate size and uniform dispersion.
As shown in Table 3, the EE and drug loading of the fresh-
prepared VANH-Lips Table 3 were 40.78% and 2.55%, which
were relatively higher than that reported previously
[14,15,18e20]. The pH of VANH-Lips was 5.96, which is
consistent with the requirements for intravenous injection.Fig. 3 e Transmission electron microscopy micrographs of
VANH-Lips: (A) fresh-prepared, (B) the suspension of
lyophilized powder.
Table 3e Physicochemical characteristics of VANH-Lips: (A) fresh-prepared, (B) the suspension of lyophilized powder, each
data was expressed as mean ± SD (n ¼ 3).
Sample Particle size (nm) PDIa EEb (%) DLc (%) pH
A 188.4 ± 5.22 0.289 ± 0.019 40.78 ± 1.04 2.55 ± 0.065 5.96 ± 0.066
B 203.7 ± 9.85 0.305 ± 0.036 35.58 ± 2.66 2.23 ± 0.166 6.02 ± 0.103
a PDI means polydispersity index.
b EE means encapsulation efficiency.
c DL means drug loading.
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reduced to 35.58% and 2.23%.This is possibly because that
VANH is so hydrophilic that it is easy to leak from the lipo-
some in the freeze-drying process.
3.3.2. In vitro drug release of VANH-Lips
In order to mimic the behavior of liposomes after intrave-
nously administration to patients, VANH-Lips were incubated
using a dialysismembrane in pH 7.4 phosphate buffer solution
at 37 C. The release experiment was carried out under sink
conditions. The accumulative release percentage profile
versus time of VANH-Lips and VANH-Sol is shown in Fig. 4.
The release profile of VANH from VANH-Lips was, further,
compared with VANH-Sol. It was apparent that almost 75% of
the drug released within 4 h of dialysis, when VANH-Sol was
dialyzed in pH 7.4 phosphate buffer solution. The VANH
release from VANH-Lips, however, did not show significant
burst release. VANH was released slower from VANH-Lips
than VANH-Sol obviously. The VANH release from VANH-
Lips was relatively slow and controlled. The release of VANH
from VANH-loaded liposomes was in accordance with the
Weibull equation and can be expressed using the following
equation: ln[1/(1eR/100)] ¼ 0.4742lnt  0.9485, r ¼ 0.9791. The
release of VANH from VANH-Sol was in accordance with the
first-order kinetic model and can be expressed using the
following equation: ln(100eR) ¼ 0.2722t þ 4.4234, r ¼ 0.9951.
This equation can be applied to forecast the release amount of0
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Fig. 4 e In vitro release profile of VANH-Sol and VANH-Lips
(n ¼ 5).VANH at different time, or calculate the time to release a
certain amount of VANH, which could predict the status of
liposomes in practical applications. The release profile of
VANH from liposomes was biphasic. The initial fast release of
around 31% of the drug from the liposomes was observed in
the first 1 h, which could probably be due to the portion of the
drug that leaked out of liposomes and the unloaded drug.3.4. Pharmacokinetics studies and drug distribution
studies in mice
3.4.1. The experimential results of pharmacokinetics
At the range of 0.5e40 mg/ml, the standard curve was
A¼ 14.699Cþ 0.1388 and the standard showed a good linearity
with a correlation coefficient of 0.9999. The blood concen-
trationetime curves of VANH in mice after intravenous
administration of a single 15 mg/kg dose of VANH-Sol and
VANH-Lips were shown in Fig. 5. The pharmacokinetic pa-
rameters calculatedbyDAS2.0 softwarewereshown inTable4.
Based on the analysis of the models and parameters, it was
concluded that the mean blood concentrationetime profiles
for both VANH-Sol and VANH-Lips were corresponded to the0
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Fig. 5 e Mean plasma concentrationetime curves of VANH
in mice after intravenous administration of VANH-Sol and
VANH-Lips at a dose of 15 mg/kg (n ¼ 5).
Table 4 e Main pharmacokinetic parameters of VANH in
mice after intravenous administration of VANH-Sol and
VANH-Lips at a single dose of 15 mg/kg.
Parameter VANH-Sol VANH-Lips
t1/2a (h) 0.145 ± 0.005* 0.101 ± 0.013*
t1/2b (h) 1.888 ± 0.067* 2.240 ± 0.066*
V1 (l/kg) 0.410 ± 0.032* 0.305 ± 0.024*
CL (l/h/kg) 0.667 ± 0.011* 0.336 ± 0.002*
AUC0e6 (mg/l$h) 18.918 ± 0.339* 36.190 ± 0.337*
AUC0e∞ (mg/l$h) 22.490 ± 0.366* 44.710 ± 0.306*
MRT0e6 (h) 1.285 ± 0.042* 1.776 ± 0.003*
MRT0e∞(h) 1.699 ± 0.198* 2.768 ± 0.021*
Symbols * denote P < 0.05.
a s i a n j o u rn a l o f p h a rma c e u t i c a l s c i e n c e s 1 0 ( 2 0 1 5 ) 2 1 2e2 2 2 219two-compartment model following intravenous administra-
tion, the weight coefficient was expressed as 1/cc.
After i.v. administration, VANH-Sol was removed from the
blood circulation of mice with a half-life of about 1.888 h. On0
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Fig. 6 e VANH concentration in tissue at different time points a
VANH-Lips (n ¼ 5).the contrary, the half-life of VANH-Lips increased to 2.240 h
compared with VANH-Sol. Furthermore, compared with
VANH-Sol, MRT0t and MRT0e∞ of VANH-Lip increased by 0.83
and 0.61 fold, respectively. The extended MRT may due to the
sustained release of VANH from VANH-Lips and the fact that
the reticuloendothelial system (RES) removal could be avoided
[28]. What's more, AUC0t and AUC0e∞ of VANH-Lips
increased about 1.13-fold and 0.99-times compared with
those of VANH-Sol, respectively. Therefore, the prolonged
blood circulation and higher AUC value of VANH-Lips may
contribute to higher therapeutic efficacy on long-periodic
treatment of osteomyelitis.
The plasma concentrationetime profile after intravenous
administration of VANH-Sol and VANH-Lips at a dose of
15 mg/kg VANH was shown in Fig. 5. The measured VANH
plasma concentration achieved from VANH-Lips group was
higher than that of the control VANH-Sol at each time point.
Then the plasma concentration of VANH-Sol declined
significantly more rapid than that of VANH-Lips. This isg kidney brain
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Fig. 7 e Kidney concentrationetime curves of VANH after
the intravenous administration of VANH-Sol and VANH-
Lips in mice (n ¼ 5). *Unit of blood drug level (mg/g).
a s i a n j o u r n a l o f p h a rma c e u t i c a l s c i e n c e s 1 0 ( 2 0 1 5 ) 2 1 2e2 2 2220possibly because that VANH was encapsulated into phos-
pholipid bilayer and released into the plasma for a prolonged
period of time. Moreover, it was reported that nanoparticles
smaller than 220 nm could escape macrophage clearance to
some extent. So the VANH-Lips can reduce clearance by
macrophage as well, which will contribute to long circulation
in blood [28]. Pharmacokinetic results in this study indicated
VANH encapsulated in liposomes retains in the blood stream
much longer than the VANH-Sol. So the VANH-Lip has more
time to interact with the APL cell, which may benefit to the
long-period clinical application of VANH.Table 5 e Biodistribution of vancomycin in liver, spleen and k
(15 mg/kg) of solution and liposome formulations.
Organs Parameter VAN
Heart AUC0e6 (mg/l h) 18.549
Cmax (mg/g) 23.474
MRT (h) 1.288
Liver AUC0e6 (mg/l h) 12.804
Cmax (mg/g) 6.245
MRT (h) 2.285
Spleen AUC0e6 (mg/l$h) 23.851
Cmax (mg/g) 6.531
MRT (h) 6.405
Lung AUC0e6 (mg/l h) 43.679
Cmax (mg/g) 19.391
MRT (h) 1.825
Kidney AUC0e6 (mg/l$h) 80.085
Cmaxv (mg/g) 29.102
MRT (h) 3.057
Brain AUC0e6 (mg/l h) 10.197
Cmax (mg/g) 3.557
MRT (h) 1.649
Re ¼ AUCVANH-Lip/AUCVANH-Sol, Symbols * denote P < 0.05.3.4.2. Drug distribution studies
Within 0.2e30 mg/ml VANH concentration, the standard
curves of all measured organs were established and the cor-
relation coefficients range from 0.9990 to 0.9997. The optimum
liposome-loaded VANH formulation by modified reverse
phase evaporation method was used to investigate the bio-
distribution of liposomal VANH in mice and evaluate its
relative retaining activities to the certain organs such as heart,
liver, spleen, lung, kidney and brain by determining the con-
centration of vancomycin hydrochloride. The tissue distribu-
tions of VANH after intravenous injection of a single 15 mg/kg
dose of VANH-Sol and VANH-Lips were shown in Fig. 6,
respectively. Remarkably, the drug distribution was different
in the VANH-Lips group and the VANH-Sol group. Briefly, the
concentration of VANH in kidney, an important excretory
organ for i.v. delivery of VANH,wasmuch lower for the VANH-
Sol group, which may be expected to reduce or avoid the po-
tential side effects to kidney. Furthermore, VANH-Lips resul-
ted in a higher drug accumulation in liver and spleen
compared with VANH-Sol (P < 0.05), which may be explained
by the fact that lipsome presented accumulative activity in
RES sites such as lung, liver and spleen [29]. Conversely the
biodistribution of VANH-Lips in non-RES sites such as in kid-
ney decreased compared with VANH-Sol, which potentially
resulted in the reduction of renal damages.
Notably, as is shown in Fig. 7, the drug concentrations in
kidey were decreased tremendously after the administration
of VANH-Lips compared with the VANH-Sol, which could
improve the efficiency of VANH and decrease the side effects.
This phenomenon may be explained by the fact that lipsome
encapsulation results in a decrease of the renal clearance [30].
The cmax, AUC and MRT values for the two groups in
different tissue were calculated and are reported in Table 5.
The tissue distribution results were evaluated according to
Re(Re¼AUCVANH-Lip/AUCVANH-Sol). If the value of Re exceeds 1,
the tissue is exposed to drug to a greater extent by theidney tissue after intravenous administration of a dose
H-Sol VANH-Lip Re
± 0.726 19.191 ± 0.154 1.040
± 1.040 19.975 ± 0.523
± 0.027 1.372 ± 2.283
± 0.375* 27.750 ± 1.039* 2.167
± 0.078 12.669 ± 0.358
± 0.066 3.054 ± 0.156
± 0.346* 47.266 ± 1.559* 1.982
± 0.277 12.469 ± 0.064
± 0.053 11.044 ± 5.778
± 0.596* 50.435 ± 0.663* 1.155
± 1.080 20.530 ± 0.440
± 0.014 1.816 ± 0.026
± 1.351* 51.631 ± 1.482* 0.645
± 2.047 16.241 ± 0.588
± 0.125 3.672 ± 0.313
± 0.164 7.647 ± 5.022 0.750
± 1.482 4.706 ± 0.203
± 0.004 1.711 ± 0.534
a s i a n j o u rn a l o f p h a rma c e u t i c a l s c i e n c e s 1 0 ( 2 0 1 5 ) 2 1 2e2 2 2 221liposomes [31]. The Re of heart, liver, spleen, lung and kidney
were 1.040, 2.167, 1.982, 1.155, 0.645 and 0.750, respectively,
shown in Table 5. It is in accordance with Fig. 6. It demon-
strated that liposomes presented accumulative activity in
reticuloendothelial system (RES) sites such as spleen and liver.
In addition, the value of Re for lung were also higher than 1,
which showed that VANH-Lipswere also inclined to distribute
to lung though less preferable to liver and spleen. Therefore
VANH-Lips performed their potential as a delivery system
targeting to lung for the treatment of pulmonary inflamma-
tion. The AUC of heart and brain were not significantly
changed. Conversely, the biodistribution of liposomes in non-
RES sites such as in kidney decreased with descending Re
compared with VANH-Sol, which potentially resulted in the
reduction of nephrotoxicity or renal damages. This prompted
the prepared VANH-Lips had the advantage in the long-
periodic treatment of osteomyelitis.4. Conclusions and outlook
In thiswork, VANH-Lipswas successfully developed. The EE of
VANH-Lips were significantly increased. The in vitro and
in vivo physicochemical properties of VANH-Lips were char-
acterized and evaluated in detail. The in vitro drug release
experiments exhibited biphasic drug release characteristic
and slower release than VANH-Sol. The pharmacokinetics
studies confirmed that the circulation time of VANH in blood
can be extended by liposome encapsulation. The tissue dis-
tribution study indicated that VANH-Lips decreased the drug
accumulation in kidney following intravenous injection in
mice. We, therefore, conclude that VANH-Lips may serve as a
promising carrier for systematic delivery of VANH in the
treatment of osteomyelitis.
Liposome as drug carriers significantly influence on drug
distribution and reduce toxic side effects during antibiotic
therapy [32e34]. In this study, VANH-Lips were found to
reduce the distribution of VANH in kidney, which might help
to lower its renal toxicity and eliminate its potential toxicity of
kidney tubules. These findings suggested that VANH-Lips
might have a potential to be developed as a promising phar-
maceutical preparation for the treatment of chronic
osteomyelitis.
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